Subtle radiographic progression at 6 months can be detected using automated quantitative software in rheumatoid arthritis while receiving tocilizumab

Taichi Okino, Yafei Ou, Masayuki Ikebe, Akira Furusaki, Akira Sagawa, Masaru Kato, Tatsuya Atsumi, Kenneth Sutherland, Tamotsu Kamishima*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: We investigated whether our in-house software equipped with partial image phase-only correlation (PIPOC) can detect subtle radiographic joint space narrowing (JSN) progression at 6 months and predict JSN progression in rheumatoid arthritis (RA) patients receiving Tocilizumab. Methods: The study included 39 RA patients who were treated with Tocilizumab. Radiological progression of the finger joints was evaluated according to the Genant-modified Sharp score (GSS) at 0, 6, and 12 months. Results: The success rate of the software for joint space width (JSW) measurement was 96.8% (449/464). The 0-12-month JSW change by the software was significantly greater in joints with the 0-6-month PIPOC (+) group than the 0-6-month PIPOC (-) group (P < 0.001). The 0-12-month JSW change by the software was 0-12 month GSS (+) than with 0-12 month GSS (-) (P = 0.02). Here, '(+)' indicates the JSN progression during the follow-up period. Linear regression tests showed significant correlations between the 0-6 month and the 0-12 month PIPOC in the left second and third metacarpophalangeal joints (R2 = 0.554 and 0.420, respectively). Conclusions: Our in-house software equipped with PIPOC could predict subsequent JSN progression with only short-term observations.

Original languageEnglish
Pages (from-to)72-78
Number of pages7
JournalModern Rheumatology
Volume35
Issue number1
DOIs
StatePublished - 2025/01/01

Keywords

  • Finger joint
  • joint space narrowing
  • radiography
  • rheumatoid arthritis
  • software

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Subtle radiographic progression at 6 months can be detected using automated quantitative software in rheumatoid arthritis while receiving tocilizumab'. Together they form a unique fingerprint.

Cite this